Another monoclonal antibody, D16F7, works against VEGFR-1 and has been shown to reduce in vivo angiogenic activity in a matrigel plug assay, as well as decreased tumor growth in mice bearing B16F10 melanoma cell tumors [178]. This evidence concerns the gene FLT1 and melanoma.